Pipeline

Palleon has translated novel discoveries in the field of glyco-immunology into a leading pipeline of first-in-class therapeutic candidates. Across its programs, glycan-mediated immunosuppression impacts both innate and adaptive immune cells concurrently. The company has designed optimized drug candiates that target this axis of immunosuppression and have the potential to overcome resistance to first generation agents that only target a single cell type.

Eagle
Eagle Drug Classification label
Drug Program
Discovery
Preclinical
CMC
IND
Phase 1
Phase 2
EAGLE-Sialidase
EAGLE-Sialidase
CMC
EAGLE-Her2
EAGLE-Her2
CMC
Undisclosed EAGLE
Undisclosed EAGLE
Preclinical
Undisclosed EAGLE
Undisclosed EAGLE
Preclinical
Convergence
Convergence Drug Classification label
Siglec-9 mAb
Siglec-9 mAb
Preclinical
Siglec-7 mAb
Siglec-7 mAb
Preclinical
Undisclosed Siglec mAb
Undisclosed Siglec mAb
Discovery
Undisclosed Siglec mAb
Undisclosed Siglec mAb
Discovery
Undisclosed Siglec mAb
Undisclosed Siglec mAb
Discovery